Hepatitis C
Newsletter
September 2012
Clinical
Trials, Cohort Studies, Pilot Studies
Active disease in chronic hepatitis C patients with
normal alanine aminotransferase. Arif A, Ahmed W, Alam
SE, Qureshi H. J Coll
Physicians Surg Pak. 2012 Aug;22(8):488-91.
http://www.ncbi.nlm.nih.gov/pubmed/22868012
Genetic variants at the ITPA
locus protect against ribavirin-induced hemolytic anemia and dose reduction in
an HCV G2/G3 cohort. Eskesen AN, Melum E, Moghaddam A, et al.. Eur J Gastroenterol
Hepatol. 2012 Aug;24(8):890-6.
http://www.ncbi.nlm.nih.gov/pubmed/22584257
Raloxifene hydrochloride is an adjuvant
antiviral treatment of postmenopausal women with chronic hepatitis C: A
randomized trial. Furusyo N, Ogawa E, Sudoh M, et
al. J Hepatol. 2012 Aug 10.
[Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22889955
The use of peginterferon
in monotherapy or in combination with ribavirin for
the treatment of acute hepatitis C. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B. Eur Rev Med Pharmacol Sci. 2012 Aug;16(8):1013-6.
http://www.ncbi.nlm.nih.gov/pubmed/22913149
RANTES, TNF-α, Oxidative
Stress, and Hematological Abnormalities in Hepatitis C Virus Infection. Tawadrous GA,
Aziz AA, Amin DG, Eldemery A, Mostafa
MA. J Investig Med. 2012 Aug;60(6):878-82.
http://www.ncbi.nlm.nih.gov/pubmed/22534629
Predictors of sustained virological response in Greek and Egyptian patients with
hepatitis C genotype 4: does ethnicity matter? Papastergiou V, Dimitroulopoulos D, Skorda L, et
al. J Med Virol. 2012 Aug;84(8):1217-23.
doi: 10.1002/jmv.23324.
http://www.ncbi.nlm.nih.gov/pubmed/22711349
Hepatitis C Virus-Specific
Cell-Mediated Immune Responses in Children Born to Mothers Infected with
Hepatitis C Virus. El-Kamary SS, Hashem M, Saleh DA, et al. J Pediatr. 2012 Aug 8. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22883419
Early
anemia and rapid virological response improve the
predictive efficiency of IL28B-genotype for treatment outcome to antiviral combination
therapy in patients infected with chronic HCV genotype 1. Amanzada A, Schneider S, Moriconi F, et al. J Med Virol.
2012 Aug;84(8):1208-16. doi: 10.1002/jmv.23323.
http://www.ncbi.nlm.nih.gov/pubmed/22711348
Basic
and Applied Science, Pre-Clinical Studies
Induction of microRNA-214-5p in human and rodent
liver fibrosis. Iizuka M, Ogawa T, Enomoto
M, Motoyama H, Yoshizato K,
Ikeda K, Kawada N. Fibrogenesis Tissue Repair. 2012
Aug 1;5(1):12. [Epub ahead
of print]
http://www.ncbi.nlm.nih.gov/pubmed/22849305
Role
of the equilibrative and concentrative nucleoside
transporters in the intestinal absorption of the nucleoside drug, ribavirin, in
wild-type and ent1(-/-) mice. Moss AM, Endres
CJ, Ruiz-Garcia A, Choi DS, Unadkat JD. Mol Pharm. 2012 Sep 4;9(9):2442-9.
Epub 2012 Aug 3.
http://www.ncbi.nlm.nih.gov/pubmed/22812541
Mutations
in non-structural 5A and rapid viral response to pegylated
interferon-α-2b plus ribavirin therapy are associated with therapeutic
efficacy in patients with genotype 1b chronic hepatitis C. Yano Y, Seo
Y, Miki A, et al. Int J Mol
Med. 2012 Aug 9. doi:
10.3892/ijmm.2012.1093. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22899224
Focal
Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected
Cells. Alisi A, Arciello
M, Petrini S, Conti B, Missale
G, Balsano C. PLoS One.
2012;7(8):e44147. Epub 2012
Aug 28.
http://www.ncbi.nlm.nih.gov/pubmed/22937161
Hepatitis
C virus translation preferentially depends on active RNA replication. Liu HM, Aizaki H, Machida K, Ou JH, Lai
MM. PLoS One. 2012;7(8):e43600. Epub 2012 Aug 24.
http://www.ncbi.nlm.nih.gov/pubmed/22937067
Human
Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in
Chimpanzees. Morin
TJ, Broering TJ, Leav BA, et
al. PLoS Pathog. 2012 Aug;8(8):e1002895. Epub 2012 Aug 30.
http://www.ncbi.nlm.nih.gov/pubmed/22952447
Quantifying the Diversification of Hepatitis C Virus
(HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate.
Ribeiro RM, Li H, Wang S, et al. PLoS Pathog. 2012 Aug;8(8):e1002881. Epub 2012 Aug 23.
http://www.ncbi.nlm.nih.gov/pubmed/22927817
Elucidation of hepatitis C virus transmission and
early diversification by single genome sequencing.
Li H, Stoddard
MB, Wang S, et al. PLoS Pathog.
2012 Aug;8(8):e1002880. Epub
2012 Aug 23.
http://www.ncbi.nlm.nih.gov/pubmed/22927816
Identification and Targeting of an Interaction between
a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for
Viral Assembly. Neveu G, Barouch-Bentov
R, Ziv-Av A, Gerber D, Jacob Y, Einav
S. PLoS Pathog. 2012 Aug;8(8):e1002845. Epub 2012 Aug 16.
http://www.ncbi.nlm.nih.gov/pubmed/22916011
Self-enhancement of hepatitis C virus replication by
promotion of specific sphingolipid biosynthesis.
Hirata Y, Ikeda
K, Sudoh M, et al. PLoS Pathog. 2012 Aug;8(8):e1002860. Epub 2012 Aug 16.
http://www.ncbi.nlm.nih.gov/pubmed/22916015
Comparison
of Hepatitis C virus subtyping by ns5b sequencing with 5'utr based methods.
Pagani E, Huemer
HP, Pasquetto V, Cemin C, Molon L, Rossi P, Larcher C. Minerva
Med. 2012 Aug;103(4):293-7.
http://www.ncbi.nlm.nih.gov/pubmed/22805621
Patient-Derived
Hepatitis C Virus and HCV JFH-1 Clones Differ in Their Ability to Infect Human Hepatoma Cells and Lymphocytes. Sarhan MA, Chen AY,
Russell RS, Michalak TI. J Gen Virol. 2012 Aug 1. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22855787
HIV/HCV
Coinfection
Hepatitis C virus genotype 4
responds better to pegylated interferon with
ribavirin than genotype 1 in HIV-infected patients. Mira
JA, Rivero A, de Los Santos-Gil I, et al. AIDS. 2012
Aug 24;26(13):1721-1724.
http://www.ncbi.nlm.nih.gov/pubmed/22695304
Virological responses during treatment for
recent hepatitis C virus: potential benefit for ribavirin use in HCV/HIV
co-infection. Grebely J, Hellard M, Applegate T, et al. AIDS. 2012
Aug 24;26(13):1653-1661.
http://www.ncbi.nlm.nih.gov/pubmed/22555168
Health Care Utilization in
HIV-Infected Patients: Assessing the Burden of Hepatitis C Virus Coinfection. Norton BL, Park L, McGrath LJ, Proeschold
Bell RJ, Muir AJ, Naggie S. AIDS Patient Care STDS.
2012 Sep;26(9):541-5. Epub
2012 Aug 3.
http://www.ncbi.nlm.nih.gov/pubmed/22860997
Hepatitis C Virus Infections in
the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic.
Wandeler G, Gsponer T, Bregenzer A, et al. Clin Infect
Dis. 2012 Aug 14. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22893583
Liver fibrosis progression in
HIV/hepatitis C virus coinfected patients with normal
amino-transferases levels. Pace
FH, Ferreira LE, Silva AE, Ferraz ML. Rev Soc Bras Med Trop. 2012 Aug;45(4):444-7.
http://www.ncbi.nlm.nih.gov/pubmed/22930041
Longitudinal
analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C
virus genotype 1a in association with the response to peginterferon
and ribavirin therapy in HIV-coinfected patients. Bolcic F, Laufer N, Torres C, Cassino L, Reynoso R, Quarleri J. Antiviral
Res. 2012 Aug;95(2):72-81. Epub
2012 Jun 7.
http://www.ncbi.nlm.nih.gov/pubmed/22683884
Complementary
and Alternative Medicine
Evidence
That Naturopathic Therapy Including Cordyceps sinensis Prolongs Survival of Patients With
Hepatocellular Carcinoma. Niwa
Y, Matsuura H, Murakami M, Sato J, Hirai K, Sumi H. Integr Cancer Ther. 2012 Aug 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22544231
Curcumin inhibits HCV replication by
induction of heme oxygenase-1 and suppression of AKT.
Chen MH, Lee MY, Chuang JJ, Li YZ, Ning ST, Chen JC, Liu YW. Int J Mol Med. 2012 Aug 20. doi: 10.3892/ijmm.2012.1096. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22922731
Epidemiology,
Diagnostics, and Miscellaneous Works
Recommendations for the identification of chronic
hepatitis C virus infection among persons born during 1945-1965.
Division
of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB
Prevention. MMWR
Recomm Rep. 2012 Aug 17;61(RR-4):1-32.
http://www.ncbi.nlm.nih.gov/pubmed/22895429
Prevalence
and correlates of HIV and HCV infection among amphetamine-type stimulant users
in 6 provinces in China.
Bao YP, Liu ZM, Lian Z, et
al. J Acquir Immune Defic Syndr. 2012 Aug 1;60(4):438-46.
http://www.ncbi.nlm.nih.gov/pubmed/22481605
Syringe
Acquisition Experiences and Attitudes among Injection Drug Users Undergoing
Short-Term Opioid Detoxification in Massachusetts and Rhode Island. Zaller ND, Yokell
MA, Nayak SM, Fu JJ, Bazazi
AR, Rich JD. J Urban Health. 2012 Aug;89(4):659-70.
http://www.ncbi.nlm.nih.gov/pubmed/22427232
Hepatitis
B and C Virus Infection Among 1.2 Million Persons With
Access to Care: Factors Associated With Testing and Infection Prevalence. Spradling PR, Rupp L, Moorman AC, et al. Clin Infect Dis. 2012 Aug 8. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22875876
Effects of patient factors on
noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. Chen
SH, Li YF, Lai HC, et al. BMC Gastroenterol. 2012 Aug
10;12(1):105. [Epub ahead of
print]
http://www.ncbi.nlm.nih.gov/pubmed/22877310
Liver
Cancer
From
cirrhosis to hepatocellular carcinoma in HCV-infected patients: genes involved
in tumor progression. Wang
Y, Li J, Chen J, Liu L, Peng Z, Ding J, Ding K. Eur Rev Med Pharmacol Sci. 2012
Aug;16(8):995-1000.
http://www.ncbi.nlm.nih.gov/pubmed/22913147
Causes of and prevention strategies for
hepatocellular carcinoma. Cabibbo G, Maida M, Genco
C, Antonucci M, Cammà C. Semin Oncol. 2012 Aug;39(4):374-83.
http://www.ncbi.nlm.nih.gov/pubmed/22846856
An
analysis of content in comprehensive cancer control plans that address chronic
hepatitis B and C virus infections as major risk factors for liver cancer. Momin B, Richardson L. J Community
Health. 2012 Aug;37(4):912-6.
http://www.ncbi.nlm.nih.gov/pubmed/22160788
Long-term
interferon monotherapy reduces the risk of
HCV-associated hepatocellular carcinoma. Takeyasu M, Akuta
N, Suzuki F, et al. J Med Virol. 2012 Aug;84(8):1199-207. doi:
10.1002/jmv.23288.
http://www.ncbi.nlm.nih.gov/pubmed/22711347
An investigation of bloodborne
pathogen transmission due to multipatient sharing of
insulin pens. Hakre S, Upshaw-Combs DR,
Sanders-Buell EE, et al. Mil Med. 2012 Aug;177(8):930-8.
http://www.ncbi.nlm.nih.gov/pubmed/22934373
Inhibition
of hepatocellular carcinoma by PegIFNα-2a in
patients with chronic hepatitis C: a nationwide multicenter cooperative study. Izumi N, Asahina
Y, Kurosaki M, et al. J Gastroenterol. 2012 Aug 9. [Epub ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22875473
Characteristics of patients with chronic hepatitis C
who develop hepatocellular carcinoma.
Kuske L, Mensen
A, Mã Llhaupt B, et al. Swiss
Med Wkly. 2012 Aug 6;142:0. doi: 10.4414/smw.2012.13651.
http://www.ncbi.nlm.nih.gov/pubmed/22869395
Comparative diagnostic efficacy of serum squamous
cell carcinoma antigen in hepatocellular carcinoma.
Soyemi OM Dr,
Otegbayo JA Dr, Ola SO Dr, Akere
A Dr, Soyemi T Dr. BMC Res
Notes. 2012 Aug 3;5(1):403. [Epub
ahead of print]
http://www.ncbi.nlm.nih.gov/pubmed/22856336
Characteristic
patterns of altered DNA methylation predict emergence of human hepatocellular
carcinoma. Nishida
N, Kudo M, Nagasaka T, Ikai I, Goel A. Hepatology. 2012 Sep;56(3):994-1003.
doi: 10.1002/hep.25706. Epub 2012 Aug 2.
http://www.ncbi.nlm.nih.gov/pubmed/22407776
A comparison of survival and pathologic features of
non-alcoholic steatohepatitis and hepatitis C virus
patients with hepatocellular carcinoma. Hernandez-Alejandro R, Croome KP, Drage M, et al. World
J Gastroenterol. 2012 Aug 21;18(31):4145-9.
http://www.ncbi.nlm.nih.gov/pubmed/22919246
Incidence of Hepatocellular Carcinoma among US
Patients with Cirrhosis of Viral or Non-Viral Etiologies.
Mair RD, Valenzuela A, Ha NB, et al. Clin Gastroenterol Hepatol. 2012 Aug 15. [Epub ahead of print]